ePrints

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

Lookup NU author(s): Noel Monks, Professor Nicola CurtinORCiD, Professor Herbie Newell

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in colorectal tumour cell-lines. Depletion of intracellular GSH using buthionine sulfoximine (BSO) resulted in only a modest potentiation of ZD2767P + CPG2 activity and hence BSO is unlikely to markedly enhance the activity of this ADEPT treatment. (C) 2000 Cancer Research Campaign.

Publication metadata

Author(s): Monks, N., Calvete, J., Curtin, N.J., Blakey, D., East, S., Newell, D.R.

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2000

Volume: 83

Issue: 2

Pages: 267-269

Print publication date: 01/01/2000

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

URL: http://dx.doi.org/10.1054/bjoc.2000.1240

DOI: 10.1054/bjoc.2000.1240

PubMed id: 10901381

Altmetrics

Share